This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.
Here is a sample of this item:
by Stockwatch Business Reporter
The TSX Venture Exchange lost 5.62 points to close at 471.74 Thursday, but it ended the month up 81.34 points. Lucas Birdsall's first capital pool shell, BMGB Capital Corp. (BMGB: halted), plans to acquire Navco Pharmaceuticals Ltd. for the shell's qualifying transaction. The shell, which has 4.5 million shares issued, will issue 14.5 million shares to its target's shareholders.
Navco Pharmaceuticals is a company in Burlington, Ont., that claims to develop and manufacture nanotechnology products for fighting micro-organisms (viruses, bacteria and fungi) as well as for protecting against gene-editing tools (lab-manufactured DNA sequences that can change genomes). The company says it has three products, including a cream that can protect the skin from micro-organisms and an aerosol spray that can protect countertops and other surfaces from micro-organisms. These products live in a crowded landscape, with store shelves already holding many similar-sounding antiviral/antibacterial/antifungal creams and antibacterial aerosol sprays.
The remainder is available to Stockwatch subscribers.
© 2020 Canjex Publishing Ltd. All rights reserved.